Open Orphan PLC hVIVO present at 2020 ERS International Congress
07 Septembre 2020 - 8:00AM
RNS Non-Regulatory
TIDMORPH
Open Orphan PLC
07 September 2020
Open Orphan plc
("Open Orphan" or the "Company")
hVIVO to present at the upcoming 2020 European Respiratory
Society (ERS) International Congress
Open Orphan plc (ORPH), a rapidly growing specialist CRO
pharmaceutical services company which is the world leader in the
testing of vaccines and antivirals using human challenge clinical
trials is pleased to announce that its subsidiary, hVIVO, will be
presenting at the European Respiratory Society Congress being held
on 7(th) - 9(th) September, 2020.
The presentation will discuss the safety and pathogenicity
results of a new RSV infection model in older adults aged
60-75-year-old. This model enables the exploration of RSV
vaccine-induced immune responses and efficacy in the context of
potential immune senescence. It also enables the potential
Identification of correlates of protection from RSV infection and
disease in one of the vaccine's target populations.
Alex J Mann, Director, Clinical Science, commented; "We are
delighted to have been accepted to present at the prestigious ERS
International Congress and share our findings. The data summarised
in the presentation and ePoster highlights the model's safety,
disease characteristics, and suitability for the further assessment
of vaccines and drugs targeted at the 60-75-year-old population, as
well as its potential to continue that progression."
Oral presentation details:
Title : Late Breaking Abstract -Experimental Respiratory
Syncytial Virus Infection in Adults 60-75 years
Authors : Alex J Mann, Maria Kalinova, Andrew Catchpole, Olesya
Rusyn, Veronika Horvathova, Kingsley Eze, Marco De Sa, Alan S
Bell
Date & Time : 9(th) September 2020 at 9:30am - 10.30am
Session Category : Airway infection: the microbiome and
beyond
Presenter: Alex J Mann, Director of Clinical Sciences
Location : Online
Conference Reference Number : Channel 4
A copy of the presentation materials and the poster can be found
here: https://hvivo.com/news-media/scientific-papers/
For further information please contact
+353 (0)1 644
Open Orphan plc 0007
Cathal Friel, Executive Chairman
Arden Partners plc (Nominated Adviser +44 (0)20 7614
and Joint Broker) 5900
John Llewellyn-Lloyd / Benjamin Cryer
/ Dan Gee-Summons
+44 (0) 20 7220
finnCap plc (Joint Broker) 500
Geoff Nash / James Thompson/ Richard Chambers
Davy (Euronext Growth Adviser and Joint +353 (0)1 679
Broker) 6363
Anthony Farrell
+44 (0)20 3757
Camarco (Financial PR) 4980
Tom Huddart / Hugo Liddy
Notes to Editors - Open Orphan:
Notes to Editors - Open Orphan:
Open Orphan is a rapidly growing niche CRO pharmaceutical
services company which is a world leader in the testing of vaccines
and antivirals through the use of human challenge clinical trials.
Conducted from Europe's only 24-bedroom quarantine clinic with
onsite virology providing individually isolated rooms and connected
to our specialist laboratory facility. hVIVO's challenge studies
require healthy volunteers to take part, volunteers are recruited
through FluCamp, learn more at www.FluCamp.com . The hVIVO facility
offers highly specialised virology and immunology laboratory
services to support pre-clinical and clinical respiratory drug,
antiviral, and vaccine discovery and development. Reliable
laboratory analysis underpinned by scientific expertise is
essential when processing and analysing clinical samples. Robust
quality processes support our team of scientists in the delivery of
submission ready data.
The Company has a leading portfolio of 8 viral challenge study
models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD
viral challenge models. As announced in early March, Open Orphan is
rapidly advancing a number of Coronavirus challenge study models
and expects to be helping many COVID-19 vaccine development
companies to test their vaccines. No other company in the world has
such a portfolio, with only two competitors globally having 1
challenge study model each. hVIVO also works with companies in the
UK and Ireland to provide COVID-19 testing to staff to protect
staff and customers from a workplace COVID-19 outbreak through its
COVID Clear offering.
Open Orphan comprises of two commercial specialist CRO services
businesses, hVIVO and Venn Life Sciences and is also developing an
early stage orphan drug genomics data platform business. This
platform captures valuable genetic data from patient populations
with specific diseases with designated orphan drug status and
incorporating AI tools. In June 2019, Open Orphan acquired
AIM-listed Venn Life Sciences Holdings plc in a reverse take-over
and in January 2020 it completed the merger with hVIVO plc in
January 2020. Venn is an integrated drug development consultancy
firm which offers CMC (chemistry, manufacturing and controls),
preclinical, Phase I & II clinical trials design and execution.
The merger with hVIVO created a European full pharma services
company broadening the Company's customer base and with
complementary specialist CRO services, widened the range of the
Company's service offerings.
About RNS Reach announcements
This is an RNS Reach announcement. RNS Reach is an investor
communication service aimed at assisting listed and unlisted
(including AIM quoted) companies to distribute non-regulatory news
releases into the public domain. Information required to be
notified under the AIM Rules for Companies, Market Abuse Regulation
or other regulation would be disseminated as an RNS regulatory
announcement and not on RNS Reach.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Private
Policy.
END
NRASSUEEMESSELU
(END) Dow Jones Newswires
September 07, 2020 02:00 ET (06:00 GMT)
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024